201 related articles for article (PubMed ID: 30146365)
1. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
[TBL] [Abstract][Full Text] [Related]
2. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
3. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
Cohen JB; Ruppert AS; Heerema NA; Andritsos LA; Jones JA; Porcu P; Baiocchi R; Christian BA; Byrd JC; Flynn J; Penza S; Devine SM; Blum KA
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):278-285.e1. PubMed ID: 25660723
[TBL] [Abstract][Full Text] [Related]
4. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
5. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
7. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C; Zheng Y; Feng Y; Cao X; Xu C
Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
[TBL] [Abstract][Full Text] [Related]
9. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
[TBL] [Abstract][Full Text] [Related]
10.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
11. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
12. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
Rücker FG; Schlenk RF; Bullinger L; Kayser S; Teleanu V; Kett H; Habdank M; Kugler CM; Holzmann K; Gaidzik VI; Paschka P; Held G; von Lilienfeld-Toal M; Lübbert M; Fröhling S; Zenz T; Krauter J; Schlegelberger B; Ganser A; Lichter P; Döhner K; Döhner H
Blood; 2012 Mar; 119(9):2114-21. PubMed ID: 22186996
[TBL] [Abstract][Full Text] [Related]
13. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
[TBL] [Abstract][Full Text] [Related]
14. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
15. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Haase D; Stevenson KE; Neuberg D; Maciejewski JP; Nazha A; Sekeres MA; Ebert BL; Garcia-Manero G; Haferlach C; Haferlach T; Kern W; Ogawa S; Nagata Y; Yoshida K; Graubert TA; Walter MJ; List AF; Komrokji RS; Padron E; Sallman D; Papaemmanuil E; Campbell PJ; Savona MR; Seegmiller A; Adès L; Fenaux P; Shih LY; Bowen D; Groves MJ; Tauro S; Fontenay M; Kosmider O; Bar-Natan M; Steensma D; Stone R; Heuser M; Thol F; Cazzola M; Malcovati L; Karsan A; Ganster C; Hellström-Lindberg E; Boultwood J; Pellagatti A; Santini V; Quek L; Vyas P; Tüchler H; Greenberg PL; Bejar R;
Leukemia; 2019 Jul; 33(7):1747-1758. PubMed ID: 30635634
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.
Ren Y; Wang J; Zhang H; Mei C; Ye L; Luo Y; Zhou X; Zhu S; Jiang L; Wang L; Jin J; Tong H
Asia Pac J Clin Oncol; 2020 Jun; 16(3):172-179. PubMed ID: 32030889
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Baliakas P; Jeromin S; Iskas M; Puiggros A; Plevova K; Nguyen-Khac F; Davis Z; Rigolin GM; Visentin A; Xochelli A; Delgado J; Baran-Marszak F; Stalika E; Abrisqueta P; Durechova K; Papaioannou G; Eclache V; Dimou M; Iliakis T; Collado R; Doubek M; Calasanz MJ; Ruiz-Xiville N; Moreno C; Jarosova M; Leeksma AC; Panayiotidis P; Podgornik H; Cymbalista F; Anagnostopoulos A; Trentin L; Stavroyianni N; Davi F; Ghia P; Kater AP; Cuneo A; Pospisilova S; Espinet B; Athanasiadou A; Oscier D; Haferlach C; Stamatopoulos K;
Blood; 2019 Mar; 133(11):1205-1216. PubMed ID: 30602617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
